GLX-derived molecule detection for IMID diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and predicting immune-mediated inflammatory diseases (IMIDs) lack effective biomarkers for early detection, disease severity, and treatment response, leading to challenges in identifying common disease characteristics and initiating targeted treatment courses.
Innovation Solution
An ex vivo method involving the measurement of glycosaminoglycans (GAGs) and proteoglycans (PGs) of the glycocalyx in biological samples to diagnose and prognosticate IMIDs, using biomarkers such as Keratan Sulfate, BiGlycan, Glypican-1, and Syndecan-3, and comparing these levels to reference values to evaluate the subject's state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for IMIDs, then general disease detection is possible, but early detection accuracy and disease-specific prediction capability are insufficient
Solution Approach 1:
The invention segments the diagnostic approach by measuring multiple individual biomarkers (syndecan-1, syndecan-4, hyaluronic acid, chondroitin sulfate, heparan sulfate) separately and evaluating their individual and combined patterns. This segmentation allows each biomarker to provide specific information about different aspects of glycocalyx degradation, improving early detection accuracy while maintaining disease-specific prediction capability through pattern analysis.
Solution Approach 2:
The invention applies a universal diagnostic method that can detect multiple types of IMIDs (rheumatoid arthritis, psoriasis, IBD, atherosclerosis, Alzheimer's disease, Parkinson's disease) using the same panel of glycocalyx biomarkers. This multi-functional approach enables early detection across different disease types while the specific biomarker patterns provide disease-specific prediction capability.
2Adaptability or versatility
If disease-specific research approaches are pursued, then specific disease mechanisms can be studied, but common disease characteristics and early inflammatory instigators are overlooked
Solution Approach 1:
The invention uses a universal panel of glycocalyx biomarkers that can be applied across multiple IMID types to identify common disease characteristics. The same measurement approach and biomarker panel detect shared inflammatory pathways and early instigators across different diseases, while the specific biomarker patterns still allow for disease-specific characterization.
Solution Approach 2:
The invention merges the detection of multiple biomarkers into a unified diagnostic approach that evaluates both common and disease-specific characteristics. By combining measurements of syndecan-1, syndecan-4, hyaluronic acid, chondroitin sulfate, and heparan sulfate, the method captures both shared inflammatory mechanisms and disease-specific patterns simultaneously.
3Quantity of substance
If proteomics is used for plasma biomarker assessment, then broad biomarker screening is possible, but pathognomonic biomarkers for disease severity and treatment response are lacking
Solution Approach 1:
The invention segments the broad proteomics screening into a focused panel of five specific glycocalyx biomarkers that have been identified as having pathognomonic value for IMIDs. This segmentation maintains comprehensive screening capability while improving measurement precision for disease severity prediction and treatment response monitoring through the selection of clinically relevant markers.
Data Source
AI summary
The present invention relates to biomarkers associated with immune-mediated inflammatory disease (IMID), particular GLX molecules, and even more particular GLX-related glycosaminglycans (GAGs) and GLX-related proteoglycans (PGs).